FIELD: medicine.
SUBSTANCE: invention concerns the pharmaceutical composition Laquinimod (5-chloro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide) in the free form and/or in the form of a pharmaceutically acceptable salt in making a finished pharmaceutical product for treating and/or relieving, and/or delaying the clinical course and progression of multiple sclerosis. As excipients, the composition contains lactose, starch and/or starch derivatives, gelatine, talc and/or paraffin.
EFFECT: invention enables extending the range of high-bioavailability products for treating multiple sclerosis.
3 cl, 5 ex
